Oryzon Genomics SA (ES:ORY)
BME:ORY
Want to see ES:ORY full AI Analyst Report?
ORY Stock Chart & Stats
€3.22
€0.02(1.34%)
At close: 4:00 PM EST
€3.22
€0.02(1.34%)
Day’s Range― - ―
52-Week Range€2.56 - €4.02
Previous CloseN/A
Volume6.85K
Average Volume (3M)1.68M
Market Cap
€246.02M
Enterprise Value€231.49M
Total Cash (Recent Filing)€31.11M
Total Debt (Recent Filing)€13.73M
Price to Earnings (P/E)―
Beta0.65
Next Earnings
Jul 29, 2026EPS Estimate
-0.06Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.06
Shares Outstanding79,887,700
10 Day Avg. Volume2,474,153
30 Day Avg. Volume1,678,358
Financial Highlights & Ratios
PEG Ratio2.31
Price to Book (P/B)2.19
Price to Sales (P/S)0.00
P/FCF Ratio-95.74
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€6.42Price Target Upside99.23% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-0.12
Revenue Forecast (FY)€8.20M
Bulls Say, Bears Say
Bulls Say
Supportive Balance SheetHealthy equity and low leverage provide durable financial flexibility for a clinical-stage biotech. This reduces near-term refinancing risk, lets management fund multiple development milestones or negotiate partnerships, and cushions the company through trial timelines and regulatory cycles.
Focused Epigenetics R&D PipelineA concentrated expertise in epigenetic therapies and clinical-stage LSD1 candidates represents a sustainable competitive advantage: domain knowledge, proprietary molecules, and multi-indication potential can attract long-term pharma partnerships and create high-value licensing or co-development opportunities.
Improving Cash-flow TrendA visible reduction in negative operating and free cash flow suggests improving operational efficiency or milestone-driven receipts. If sustained, this trend lowers future funding frequency, extends runway, and increases strategic optionality for partnerships or selective pipeline investment.
Bears Say
Persistent Operating LossesOngoing operating and net losses are a structural constraint: they necessitate repeated capital raises or partner deals, dilute shareholders, and mean the firm remains dependent on clinical success and external funding before achieving sustainable profitability.
Chronic Cash BurnNegative operating cash flow each year signals a persistent financing need. This elevates dilution and refinancing risk, limits the ability to scale programs simultaneously, and makes long-term planning vulnerable to market conditions or partner deal timing.
Irregular, Volatile RevenueRepeated zero-revenue periods indicate dependence on irregular one-off payments or milestone income rather than sustainable sales. This unpredictability complicates cash planning, reduces visibility for investors/partners, and increases execution risk until recurring revenue sources emerge.
Oryzon Genomics SA News
ORY FAQ
What was Oryzon Genomics SA’s price range in the past 12 months?
Oryzon Genomics SA lowest stock price was €2.56 and its highest was €4.02 in the past 12 months.
What is Oryzon Genomics SA’s market cap?
Oryzon Genomics SA’s market cap is €246.02M.
When is Oryzon Genomics SA’s upcoming earnings report date?
Oryzon Genomics SA’s upcoming earnings report date is Jul 29, 2026 which is in 42 days.
How were Oryzon Genomics SA’s earnings last quarter?
Oryzon Genomics SA released its earnings results on May 14, 2026. The company reported -€0.017 earnings per share for the quarter, the consensus estimate of -€0.017 by €0.
Is Oryzon Genomics SA overvalued?
According to Wall Street analysts Oryzon Genomics SA’s price is currently Undervalued.
Does Oryzon Genomics SA pay dividends?
Oryzon Genomics SA does not currently pay dividends.
What is Oryzon Genomics SA’s EPS estimate?
Oryzon Genomics SA’s EPS estimate is -0.06.
How many shares outstanding does Oryzon Genomics SA have?
Oryzon Genomics SA has 79,887,700 shares outstanding.
What happened to Oryzon Genomics SA’s price movement after its last earnings report?
Oryzon Genomics SA reported an EPS of -€0.017 in its last earnings report, expectations of -€0.017. Following the earnings report the stock price went up 2.253%.
Which hedge fund is a major shareholder of Oryzon Genomics SA?
Currently, no hedge funds are holding shares in ES:ORY
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Oryzon Genomics SA
Oryzon Genomics S.A. is a biopharmaceutical company in the clinical development stage, dedicated to identifying and advancing epigenetic therapies for individuals suffering from cancer and central nervous system (CNS) conditions. The company's pipeline features two primary clinical-stage compounds: iadademstat (ORY-1001), a specific LSD1 inhibitor undergoing Phase II trials for various cancers, and vafidemstat (ORY-2001), an LSD1 inhibitor optimized for central nervous system applications, currently in Phase II development for neurological and psychiatric illnesses. Additionally, ORY-3001, another LSD1 inhibitor, is among its product candidates, presently in preclinical development to address non-cancerous diseases. Established in 2000, Oryzon Genomics S.A. is headquartered in Cornellà de Llobregat, Spain.
ORY Stock 12 Month Forecast
Average Price Target
€6.42
▲(99.23% Upside)
Technical Analysis
Options Prices
Currently, No data available
---